Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE BESYLATE VALSARTAN AND HYDROCHLOROTHIAZIDE versus BENICAR HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE BESYLATE VALSARTAN AND HYDROCHLOROTHIAZIDE versus BENICAR HCT.
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE vs BENICAR HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, causing vasodilation and reduced peripheral resistance. Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone release. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, increasing sodium and water excretion.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
One tablet orally once daily. Available strengths: amlodipine 5 mg/valsartan 160 mg/HCTZ 12.5 mg, amlodipine 5 mg/valsartan 160 mg/HCTZ 25 mg, amlodipine 10 mg/valsartan 160 mg/HCTZ 12.5 mg, amlodipine 10 mg/valsartan 160 mg/HCTZ 25 mg, amlodipine 10 mg/valsartan 320 mg/HCTZ 25 mg. Titrate based on response, max dose: amlodipine 10 mg/valsartan 320 mg/HCTZ 25 mg daily.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
None Documented
None Documented
Amlodipine: 30-50 hours (terminal, allows once-daily dosing); Valsartan: 6 hours; Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Amlodipine: 60% renal, 20-25% biliary/fecal; Valsartan: 83% fecal via bile, 13% renal; Hydrochlorothiazide: ≥95% renal as unchanged drug.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Category D/X
Category C
ARB
ARB + Thiazide Diuretic